Emerald Advisers LLC lifted its holdings in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 5.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 719,217 shares of the company's stock after purchasing an additional 38,230 shares during the period. Emerald Advisers LLC owned 1.88% of Quanterix worth $9,321,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in QTRX. nVerses Capital LLC bought a new stake in shares of Quanterix during the third quarter worth $60,000. SG Americas Securities LLC bought a new stake in shares of Quanterix during the third quarter worth $139,000. Canada Pension Plan Investment Board bought a new stake in shares of Quanterix during the second quarter worth $140,000. Hsbc Holdings PLC grew its holdings in shares of Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company's stock worth $164,000 after purchasing an additional 3,279 shares during the last quarter. Finally, Comerica Bank grew its holdings in shares of Quanterix by 44,205.6% during the first quarter. Comerica Bank now owns 7,975 shares of the company's stock worth $188,000 after purchasing an additional 7,957 shares during the last quarter. Institutional investors own 86.48% of the company's stock.
QTRX has been the topic of several research analyst reports. The Goldman Sachs Group decreased their target price on Quanterix from $35.00 to $24.00 and set a "buy" rating on the stock in a report on Tuesday, July 9th. TD Cowen decreased their price target on Quanterix from $17.00 to $15.00 and set a "hold" rating on the stock in a report on Friday, August 9th. Finally, Scotiabank decreased their price target on Quanterix from $32.00 to $28.00 and set a "sector outperform" rating on the stock in a report on Monday, August 12th.
Check Out Our Latest Stock Analysis on Quanterix
Quanterix stock traded up $0.21 during mid-day trading on Friday, hitting $13.43. The stock had a trading volume of 383,841 shares, compared to its average volume of 336,757. The stock has a 50-day simple moving average of $12.71 and a two-hundred day simple moving average of $14.09. The stock has a market capitalization of $515.44 million, a PE ratio of -12.79 and a beta of 1.36. Quanterix Co. has a 12 month low of $10.50 and a 12 month high of $29.70.
Quanterix (NASDAQ:QTRX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Quanterix had a negative net margin of 30.71% and a negative return on equity of 11.52%. The company had revenue of $34.38 million during the quarter, compared to analyst estimates of $34.19 million. During the same period in the previous year, the company posted ($0.16) EPS. Sell-side analysts expect that Quanterix Co. will post -0.88 earnings per share for the current fiscal year.
In related news, Director David R. Walt bought 47,000 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were purchased at an average price of $13.29 per share, with a total value of $624,630.00. Following the completion of the purchase, the director now owns 1,487,342 shares of the company's stock, valued at $19,766,775.18. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.90% of the company's stock.
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.